December 2022

The initial results of the long-awaited BEST-CLI (Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia) trial were recently published in the New England Journal of Medicine. There is a lack of prospective, randomized data to guide treatment of peripheral arterial disease, and this landmark trial is worthy of review and analysis by any practitioner treating CLTI.

Peripheral artery disease (PAD) represents an important cause of morbidity and mortality worldwide. In general, women are a particularly susceptible population for their sex differences with men in the development of the disease. The pathophysiology, risk factors, clinical presentation, diagnosis, management, outcomes, and quality of life of women with PAD are reviewed herein.

The study objective is to better define historical graft patency rates and adverse events following surgical bypass for femoral-popliteal arterial disease in patients with and without critical limb ischemia and compare them with contemporary studies.

The current study describes the underlying rationale, objectives, and methods to explore PAD, CLI, and CKD associations.

Consecutive patients scheduled for transfemoral TAVI were retrospectively grouped according to vascular access (percutaneous access and surgical cutdown). Primary endpoints were vascular and bleeding complications and 30-day mortality.

Our study aims to determine whether racial and gender differences exist between Hispanic and non-Hispanic Americans regarding access and treatment for PAD care.